Document is current
Any future updates will be listed below
-
Authors
Ochi, Sae
Sonomoto, Koshiro
Nakayamada, Shingo
Tanaka, Yoshiya
- License Information
-
More Information
Article History
Received: 19 February 2024
Accepted: 5 July 2024
First Online: 26 July 2024
Declarations
:
: This study was carried out in compliance with the Helsinki Declaration and was approved by the ethics review board of the University of Occupational and Environmental Health, Japan (approval number 04–23).
: Informed consent was obtained from all patients of the FIRST Registry.
: YT has received speaking fees and/or honoraria from Eli Lilly, AstraZeneca, Abbvie, Gilead, Chugai, Behringer-Ingelheim, GlaxoSmithKline, Eisai, Taisho, Bristol-Myers, Pfizer, Taiho, received research grants from Mitsubishi-Tanabe, Eisai, Chugai, Taisho.SO has received speaking fees from Asahi-kasei, Astellas, Eisai, Janssen, Mitsubishi-Tanabe, and Taisho Pharmaceutical Holdings.S N has received consulting fees, speaking fees, lecture fees, and/or honoraria from AstraZeneca, GlaxoSmithKline, Pfizer, Bristol-Myers, Astellas, Asahi-kasei, AbbVie, Chugai, Sanofi, Eisai, Gilead Sciences, Mitsubishi-Tanabe, Janssen, Eli Lilly, and Ayumi.KS declares that there are no competing interests. SO has received speaking fees from Asahi-kasei, Astellas, Eisai, Janssen, Mitsubishi-Tanabe, and Taisho Pharmaceutical Holdings. S N has received consulting fees, speaking fees, lecture fees, and/or honoraria from AstraZeneca, GlaxoSmithKline, Pfizer, Bristol-Myers, Astellas, Asahi-kasei, AbbVie, Chugai, Sanofi, Eisai, Gilead Sciences, Mitsubishi-Tanabe, Janssen, Eli Lilly, and Ayumi. KS declares that there are no competing interests.
